BVT Call 52 BMY 20.09.2024/ DE000VM7NZ60 /
| 2024-05-24 8:02:19 PM | Chg.-0.002 | Bid9:59:32 PM | Ask9:59:32 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.018EUR | -10.00% | - Bid Size: - |
- Ask Size: - |
Bristol Myers Squibb... | 52.00 USD | 2024-09-20 | Call |
GlobeNewswire
05-23
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
05-23
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire
05-14
Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-13
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Immunocore reports first quarter financial results and provides a business update
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-02
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-30
CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical D...
GlobeNewswire
04-25
International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...
GlobeNewswire
04-25
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...
GlobeNewswire
04-25
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
